Femasys Inc. (NASDAQ:FEMY) Short Interest Update

Femasys Inc. (NASDAQ:FEMY) was the recipient of a significant decline in short interest during the month of June. As of June 15th, there was short interest totaling 198,600 shares, a decline of 94.0% from the May 31st total of 3,326,404 shares. Currently, 7.1% of the company’s stock are short sold. Based on an average daily volume of 78,232 shares, the days-to-cover ratio is presently 2.5 days.

Wall Street Analyst Weigh In

Several equities analysts have commented on FEMY shares. Lake Street Capital initiated coverage on shares of Femasys in a research note on Tuesday, March 3rd. They issued a “buy” rating and a $30.00 price target on the stock. Wall Street Zen upgraded shares of Femasys to a “hold” rating in a research report on Saturday, June 13th. Finally, Weiss Ratings upgraded shares of Femasys from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, June 3rd. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $106.67.

Femasys Stock Performance

Shares of NASDAQ FEMY traded down $0.07 during trading hours on Thursday, reaching $3.60. The stock had a trading volume of 48,838 shares, compared to its average volume of 64,095. The firm has a 50-day moving average of $6.83 and a 200-day moving average of $9.97. The firm has a market cap of $10.87 million, a price-to-earnings ratio of -0.67 and a beta of -2.23. The company has a current ratio of 3.91, a quick ratio of 1.98 and a debt-to-equity ratio of 0.53. Femasys has a fifty-two week low of $3.50 and a fifty-two week high of $22.20.

Femasys (NASDAQ:FEMY) last released its quarterly earnings results on Friday, May 8th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of ($1.33) by $1.43. Femasys had a negative return on equity of 258.08% and a negative net margin of 521.97%.The company had revenue of $0.42 million for the quarter, compared to analyst estimates of $0.77 million.

Hedge Funds Weigh In On Femasys

A number of institutional investors have recently modified their holdings of FEMY. State Street Corp raised its position in Femasys by 43.5% in the 4th quarter. State Street Corp now owns 80,869 shares of the company’s stock valued at $47,000 after purchasing an additional 24,500 shares during the last quarter. Kovack Advisors Inc. purchased a new position in Femasys during the 4th quarter worth $27,000. Osaic Holdings Inc. purchased a new position in Femasys during the 2nd quarter worth $45,000. HRT Financial LP acquired a new position in Femasys in the fourth quarter valued at $30,000. Finally, Cetera Investment Advisers acquired a new position in Femasys in the fourth quarter valued at $36,000. 65.27% of the stock is owned by institutional investors and hedge funds.

Femasys Company Profile

Femasys International, Inc is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care.

The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography.